Onconetix (ONCO) AI Stock Analysis

• Market Cap: $2.25M
• Dividend Yield: N/A
• Average Volume (3M): 175.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.34
• Revenue Growth: N/A
• EPS Growth: -97.16%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -88.84
• Shares Outstanding: 521,863
• 10 Day Avg. Volume: 131,330
• 30 Day Avg. Volume: 175,497
• PEG Ratio: <0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.34
• Enterprise Value/Market Cap: 4.43
• Enterprise Value/Revenue: 1.28
• Enterprise Value/Gross Profit: 10.94
• Enterprise Value/Ebitda: -0.05
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 33 Underperform
• Price Target: ―

Onconetix's overall score reflects substantial financial difficulties with significant operating losses and negative profitability metrics. The technical analysis suggests a bearish trend, and the valuation metrics are unfavorable due to negative earnings. These factors combine to give the stock a low attractiveness score.

Onconetix Business Overview & Revenue Model

Company Description

Onconetix (ONCO) is a biotechnology company specializing in the development and commercialization of innovative cancer diagnostics and therapeutics. The company operates in the healthcare and life sciences sectors, focusing on leveraging advanced technologies to improve cancer detection, treatment, and patient outcomes. Onconetix's core products include a range of diagnostic assays and personalized treatment solutions designed to target specific cancer biomarkers, thereby enabling more effective and tailored treatment regimens.

How the Company Makes Money

Onconetix makes money primarily through the sale of its diagnostic assays and therapeutic solutions to healthcare providers, research institutions, and pharmaceutical companies. The company generates revenue by licensing its proprietary technologies and intellectual property to other firms in the oncology space. Additionally, Onconetix may engage in strategic partnerships and collaborations with larger biotech and pharmaceutical companies to co-develop and commercialize its products, sharing in the profits generated from these joint ventures. Revenues may also be supplemented by grants and funding from government and non-profit organizations dedicated to cancer research and innovation.

Onconetix Financial Statement Overview

Summary

Onconetix is facing significant financial challenges, characterized by substantial operating losses, negative profit margins, and strained cash flows. While there is some revenue growth, the overall financial health is weakened by high costs, negative equity returns, and operational cash deficits. The company's leverage is moderate but requires careful management to avoid liquidity issues.

Income Statement

Onconetix's income statement shows significant challenges with negative profitability metrics. The TTM gross profit margin is negative due to higher costs than revenues, and net income is deeply negative, resulting in a net profit margin of -2758.4%. The company has shown some revenue growth, as seen from a significant increase in TTM revenue compared to previous years, but this is outweighed by the high operating losses.

Balance Sheet

The balance sheet reflects a high debt-to-equity ratio of 0.29, indicating moderate leverage. The return on equity (ROE) is negative due to persistent net losses, and the equity ratio stands at 54.8%, suggesting a fair proportion of equity in the capital structure. However, the decline in stockholders' equity and total assets over the period indicates potential financial strain.

Cash Flow

Cash flow metrics highlight operational difficulties, with negative free cash flow and a free cash flow to net income ratio of 0.15, indicating limited cash generation relative to net losses. Despite some financing cash inflows, the operating cash flow remains negative, which is concerning for sustainable operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.93M	2.52M	58.47K	0.00	0.00	0.00
Gross Profit	911.93K	1.06M	-1.13M	-6.75K	-4.89K	-3.06K
EBITDA	-55.29M	-57.60M	-36.71M	-13.54M	-3.41M	-1.62M
Net Income	-56.12M	-58.69M	-37.41M	-13.42M	-3.42M	-1.60M
Balance Sheet
Total Assets	18.78M	28.18M	87.52M	26.31M	3.08M	4.81M
Cash, Cash Equivalents and Short-Term Investments	1.58M	646.50K	4.55M	25.75M	1.93M	4.31M
Total Debt	9.05M	9.45M	9.89M	0.00	0.00	0.00
Total Liabilities	14.26M	18.57M	23.18M	3.92M	1.64M	78.31K
Stockholders Equity	4.52M	9.61M	58.63M	22.39M	1.45M	4.73M
Cash Flow
Free Cash Flow	-7.29M	-10.52M	-13.64M	-8.71M	-2.05M	-1.74M
Operating Cash Flow	-7.26M	-10.50M	-13.58M	-8.70M	-2.04M	-1.73M
Investing Cash Flow	-23.89K	-28.47K	-8.65M	-9.34K	-1.92K	-11.79K
Financing Cash Flow	4.41M	6.74M	1.04M	32.53M	-334.19K	0.00

Onconetix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ONCO, the sentiment is Negative. The current price of 4.8 is below the 20-day moving average (MA) of 4.86, below the 50-day MA of 5.83, and below the 200-day MA of 92.88, indicating a bearish trend. The MACD of -0.43 indicates Negative momentum. The RSI at 45.56 is Neutral, neither overbought nor oversold. The STOCH value of 53.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ONCO.

Onconetix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	84 Outperform	$12.04B	19.74	30.22%	―	24.49%	244.87%
INCY	74 Outperform	$13.02B	209.38	0.47%	―	17.13%	-88.78%
BMRN	71 Outperform	$11.01B	21.52	9.64%	―	17.99%	152.10%
GILD	71 Outperform	$139.05B	23.50	32.51%	2.85%	4.63%	1144.01%
Sector *	64 Neutral	CHF27.27B	19.56	9.37%	2.21%	35.83%	-1.90%
VRTX	61 Neutral	$117.98B	―	-5.64%	―	8.55%	-124.45%
ONCO	33 Underperform	$2.25M	―	-237.69%	―	―	-97.16%